Furthermore, given its cell surface localization and functional role in tumor biology, Claudin-4 represents an attractive therapeutic target, as evidenced by ongoing clinical trials and early translational studies investigating Claudin-targeted antibodies and ADCs in gastrointestinal and gynecologic cancers [43]. Here, CLDN4 is linked to neoplasm.